Skip to main content
. 2022 Nov 22;11(23):6898. doi: 10.3390/jcm11236898
AKI acute kidney injury
ARC augmented renal clearance
AUC area under the concentration time curve
BLBLI β-lactam/β-lactamase inhibitors
BLI β-lactamase inhibitors
BMI body mass index
CAZ/AVI ceftazidime/avibactam
CFR cumulative fraction of response
CFU colony-forming units
C.I continuous infusion
CL clearance
Cmax maximum concentration
Cmin minimal concentration
CrCL creatinine clearance
CRRT continuous renal replacement therapy
CT threshold of concentration
C/T ceftolozane/tazobactam
CVVH continuous venovenous hemofiltration
CVVHD continuous venovenous hemodialysis
CVVHDF continuous venovenous hemodiafiltration
ECMO extracorporeal membrane oxygenation
E.I extended infusion
g gram
h hour
ICUs intensive care units
IMI/REL imipenem/relebactam
LD loading dose
MDR multidrug-resistant
MEV meropenem/vaborbactam
MIC minimum inhibitory concentration
MRSE methicillin-resistant S. epidermidis
PICO population, intervention, comparator, outcome
PIRRT prolonged intermittent renal replacement therapy
PK/PD pharmacokinetic/pharmacodynamic
PsA Pseudomonas aeruginosa
PTA probability of target attainment
Qxh every x hours
RRT renal replacement therapy
TDM therapeutic drug monitoring
VA-ECMO venoarterial ECMO
Vd volume of distribution
VV-ECMO venovenous ECMO
%ƒT > MIC percentage of free drug concentration above MIC